EBMT is participating in two European funded projects: Minerva and EHDEN.
The Minerva project is led by the European Medicines Agency and is aimed at ‘strengthening the use of real-world data in medicines development: metadata for data discoverability and study replicability’. One of the challenges for regulators is the identification of suitable data sources that are appropriate for a specific study. Metadata is a useful tool as it is a set of data that describes and gives information about other data. EBMT is one of the real-world data sources that will be characterized with a common set of metadata. By participating in this project EBMT will contribute to the characterization and discoverability of the valuable data we have in our Registry as well as the development of a good practice guide on metadata.
The European Health Data & Evidence Network (EHDEN) aims to provide a new paradigm for the discovery and analysis of health data in Europe by building a large-scale, federated network of data sources standardized to a common data model. This project has received funding from the Innovative Medicines Initiative (IMI) which in turn receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. EBMT has been selected as a data partner and in the second half of 2021 we will map the EBMT Registry Data to the OMOP-CDM (Observational medical outcomes partnership - Common Data Model). For this exercise, we get expert support from a small medium enterprise that is specialised in this area. By adopting the OMOP-CDM, EBMT will improve interoperability and characterisation of our Registry data which in turn will facilitate the use of EBMT data for scientific collaboration, research and healthcare decision-making.